WO2005026192A3 - Hpv cd8+ t-cell epitopes - Google Patents

Hpv cd8+ t-cell epitopes Download PDF

Info

Publication number
WO2005026192A3
WO2005026192A3 PCT/US2004/027271 US2004027271W WO2005026192A3 WO 2005026192 A3 WO2005026192 A3 WO 2005026192A3 US 2004027271 W US2004027271 W US 2004027271W WO 2005026192 A3 WO2005026192 A3 WO 2005026192A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
hpv
provides
cell epitopes
epitopes
Prior art date
Application number
PCT/US2004/027271
Other languages
French (fr)
Other versions
WO2005026192A2 (en
Inventor
Fiona A Harding
Jeanette Marie Mucha
Original Assignee
Innogenetics Nv
Fiona A Harding
Jeanette Marie Mucha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv, Fiona A Harding, Jeanette Marie Mucha filed Critical Innogenetics Nv
Publication of WO2005026192A2 publication Critical patent/WO2005026192A2/en
Publication of WO2005026192A3 publication Critical patent/WO2005026192A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Abstract

The present invention provides means to identify functional CD8+ T- cell epitopes in any protein of interest. The present invention further provides CD8+ T- cell epitopes of various proteins. In additional embodiments, the present invention provides epitopes suitable for use in prophylactic and/or therapeutic vaccines. In particularly preferred embodiments, the present invention provides modified epitopes suitable for use in prophylactic and/or therapeutic vaccines. In some preferred embodiments, the present invention provides means for the development of HPV vaccines, in particular multivalent vaccines for the prevention of infection with high- risk HPV strains. In particular, the present invention provides means to identify CD8+ T- cell epitopes in HPV strains such as HPV 16 and HPV 18. In additional embodiments, the present invention provides means for the development of therapeutic vaccines against high- risk HPV types that prevent the development of begnin and/or malignant tumors in infected individuals. The present invention further provides epitopes suitable for use in prophylactic and therapeutic vaccines.
PCT/US2004/027271 2003-09-05 2004-08-23 Hpv cd8+ t-cell epitopes WO2005026192A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50045203P 2003-09-05 2003-09-05
US60/500,452 2003-09-05

Publications (2)

Publication Number Publication Date
WO2005026192A2 WO2005026192A2 (en) 2005-03-24
WO2005026192A3 true WO2005026192A3 (en) 2005-05-12

Family

ID=34312196

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/027263 WO2005025497A2 (en) 2003-09-05 2004-08-23 Hpv cd8+ t-cell epitopes
PCT/US2004/027271 WO2005026192A2 (en) 2003-09-05 2004-08-23 Hpv cd8+ t-cell epitopes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027263 WO2005025497A2 (en) 2003-09-05 2004-08-23 Hpv cd8+ t-cell epitopes

Country Status (10)

Country Link
US (2) US7153659B2 (en)
EP (1) EP1660686B1 (en)
JP (1) JP4647606B2 (en)
CN (1) CN1846000B (en)
AT (1) ATE557099T1 (en)
AU (1) AU2004271951B2 (en)
CA (1) CA2536735C (en)
MX (1) MXPA06002311A (en)
NZ (1) NZ545364A (en)
WO (2) WO2005025497A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papilloma virus for use in human t cell response inducing compositions
DK1572994T3 (en) * 2002-12-20 2007-05-29 Chromagenics Bv Means and Methods for Preparing a Protein Through Chromatin Openers That Can Make Chromatin More Available for Transcription Factors
US20060172382A1 (en) * 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2010040847A2 (en) 2008-10-10 2010-04-15 Era Biotech, S.A. Recombinant protein bodies as immunogen-specific adjuvants
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2015097077A2 (en) 2013-12-27 2015-07-02 F. Hoffmann-La Roche Ag Systemic discovery, maturation and extension of peptide binders to proteins
AU2016251501A1 (en) 2015-04-20 2017-10-19 F. Hoffmann-La Roche Ag Specific peptide binders to proteins identified via systemic discovery, maturation and extension process
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US5922687A (en) * 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
US6962790B1 (en) * 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
WO2002022648A2 (en) 2000-09-15 2002-03-21 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
US20030003485A1 (en) * 2001-05-15 2003-01-02 Ludwig Institute For Cancer Research Methods for identifying antigens
US20030124718A1 (en) * 2001-05-18 2003-07-03 Deborah Fuller Vaccine composition
FR2837837B1 (en) * 2002-03-28 2006-09-29 Roussy Inst Gustave PEPTIDE EPITOPES COMMON TO ANTIGENS OF THE SAME MULTIGENIC FAMILY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5415995A (en) * 1986-07-10 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods

Also Published As

Publication number Publication date
US20050181458A1 (en) 2005-08-18
EP1660686A4 (en) 2009-07-22
US7329498B2 (en) 2008-02-12
EP1660686B1 (en) 2012-05-09
EP1660686A2 (en) 2006-05-31
CN1846000B (en) 2012-10-03
US20070128630A1 (en) 2007-06-07
CA2536735C (en) 2013-01-22
MXPA06002311A (en) 2006-05-19
AU2004271951A1 (en) 2005-03-24
WO2005025497A3 (en) 2005-06-02
ATE557099T1 (en) 2012-05-15
JP2007503830A (en) 2007-03-01
NZ545364A (en) 2009-06-26
CA2536735A1 (en) 2005-03-24
CN1846000A (en) 2006-10-11
US7153659B2 (en) 2006-12-26
WO2005026192A2 (en) 2005-03-24
AU2004271951B2 (en) 2008-08-21
JP4647606B2 (en) 2011-03-09
WO2005025497A2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005026192A3 (en) Hpv cd8+ t-cell epitopes
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2006037979A3 (en) Nanoparticles comprising antigens and adjuvants and immunogenic structure
HUP0303199A2 (en) Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
HUP0402067A2 (en) Vaccines
ATE426412T1 (en) ADJUVANT INFLUENZA VACCINE
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
TR200102739T2 (en) Vaccine
WO1999041383A8 (en) Antigen library immunization
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2002102299A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO2005046449A3 (en) Soluble tcr molecules and methods of use
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2002024739A3 (en) Spas-1 cancer antigen
WO2004031230A3 (en) Novel mhc ii associated peptides
WO2004098497A3 (en) Cd4+ human papillomavirus (hpv) epitopes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase